cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up . N Engl J Med 1995 ; 332 : 901 – 906 . 6 Budman DR Berry DA Cirrincione CT . Dose and dose intensity as determinants of outcome in
Search Results
Tobin Strom, Javier F. Torres-Roca, Akash Parekh, Arash O. Naghavi, Jimmy J. Caudell, Daniel E. Oliver, Jane L. Messina, Nikhil I. Khushalani, Jonathan S. Zager, Amod Sarnaik, James J. Mulé, Andy M. Trotti, Steven A. Eschrich, Vernon K. Sondak, and Louis B. Harrison
included. Demographic, histopathologic, radiation, and outcome data were reviewed. Patients were treated with either SLNB alone (n=49) or followed by completion LND (n=270) or therapeutic LND (n=91). Most patients with a known primary underwent wide
Guru Subramanian Guru Murthy, Aniko Szabo, Laura Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Sameem Abedin, and Ehab Atallah
), and other agents, has remarkably transformed the outcomes of this disorder, with current cure rates exceeding 90%. 2 – 5 However, this result is often a projection of data from clinical trials that included carefully selected patients and may not
Ryan D. Nipp, Brandon Temel, Charn-Xin Fuh, Paul Kay, Sophia Landay, Daniel Lage, Esteban Franco-Garcia, Erin Scott, Erin Stevens, Terrence O’Malley, Supriya Mohile, William Dale, Lara Traeger, Ardeshir Z. Hashmi, Vicki Jackson, Joseph A. Greer, Areej El-Jawahri, and Jennifer S. Temel
population accounts for nearly three-fourths of cancer deaths. 1 Older adults diagnosed with cancer also experience worse survival outcomes than their younger counterparts, which may result from differential treatment of the geriatric cancer population. 2
Yue Chen, Zi-Qi Zheng, Fo-Ping Chen, Jian-Ye Yan, Xiao-Dan Huang, Feng Li, Ying Sun, and Guan-Qun Zhou
the role of PORT in survival outcome, which would help surgeons and radiologists provide individualized recommendations regarding PORT to patients with ACC. Patients and Methods Patient Characteristics From January 2000 through December 2017, 480
Daniel Boakye, Viola Walter, Lina Jansen, Uwe M. Martens, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner
recurrence-related outcomes is limited. It is also unclear whether the impact of comorbidities varies by tumor stage or site. In some previous studies, the effect of comorbidity on overall survival (OS) appeared to be more pronounced in patients with early
Charlotte E.L. Klaver, Lieke Gietelink, Willem A. Bemelman, Michel W.J.M. Wouters, Theo Wiggers, Rob A.E.M. Tollenaar, Pieter J. Tanis, and on behalf of the Dutch Surgical Colorectal Audit Group
Dutch Surgical Colorectal Audit (DSCA) has been evaluating and reporting on the quality of care of primary CRC surgery since 2009. 7 , 8 The goal of this study was to evaluate current clinical practice regarding and short-term outcomes of the treatment
Thomas A. D’Amico, Lindsey A.M. Bandini, Alan Balch, Al B. Benson III, Stephen B. Edge, C. Lyn Fitzgerald, Robert J. Green, Wui-Jin Koh, Michael Kolodziej, Shaji Kumar, Neal J. Meropol, James L. Mohler, David Pfister, Ronald S. Walters, and Robert W. Carlson
currently accepted framework for quality measurement in oncology, in part based on the structure, process, and outcome model for assessment of healthcare quality defined in the 1960s by Avedis Donabedian. 2 Shortly thereafter, the National Quality Forum
Sarju Ganatra, Sourbha S. Dani, Robert Redd, Kimberly Rieger-Christ, Rushin Patel, Rohan Parikh, Aarti Asnani, Vigyan Bang, Katherine Shreyder, Simarjeet S. Brar, Amitoj Singh, Dhruv S. Kazi, Avirup Guha, Salim S. Hayek, Ana Barac, Krishna S. Gunturu, Corrine Zarwan, Anne C. Mosenthal, Shakeeb A. Yunus, Amudha Kumar, Jaymin M. Patel, Richard D. Patten, David M. Venesy, Sachin P. Shah, Frederic S. Resnic, Anju Nohria, and Suzanne J. Baron
the highest risk of mortality. 1 – 8 Although both cancer and CVD have been independently associated with higher COVID-19–associated adverse outcomes, outcomes for patients with COVID-19 afflicted with a dual diagnosis of cancer and
Sarju Ganatra, Sourbha S. Dani, Robert Redd, Kimberly Rieger-Christ, Rushin Patel, Rohan Parikh, Aarti Asnani, Vigyan Bang, Katherine Shreyder, Simarjeet S. Brar, Amitoj Singh, Dhruv S. Kazi, Avirup Guha, Salim S. Hayek, Ana Barac, Krishna S. Gunturu, Corrine Zarwan, Anne C. Mosenthal, Shakeeb A. Yunus, Amudha Kumar, Jaymin M. Patel, Richard D. Patten, David M. Venesy, Sachin P. Shah, Frederic S. Resnic, Anju Nohria, and Suzanne J. Baron
highest risk of mortality. 1 – 8 Although both cancer and CVD have been independently associated with higher COVID-19–associated adverse outcomes, outcomes for patients with COVID-19 afflicted with a dual diagnosis of cancer and CVD are not well
